Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

67.74 +1.97 (+3.00%)
Official Closing Price Updated: 6:30 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,252,623
Open 64.09
Bid (Size) 66.90 (1)
Ask (Size) 67.25 (8)
Prev. Close 65.77
Today's Range 64.04 - 67.75
52wk Range 57.00 - 148.15
Shares Outstanding N/A
Dividend Yield 3.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Big News! U.S. and China Trade Deal Shakes Up Markets
Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us. 
Via The Motley Fool
Topics World Trade
Exposures Tariff
Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders
Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders. 
Via Benzinga

Performance

YTD
-22.6%
-22.6%
1 Month
+4.7%
+4.7%
3 Month
-19.3%
-19.3%
6 Month
-37.9%
-37.9%
1 Year
-48.8%
-48.8%

More News

Read More
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims'
Via Benzinga
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
Via Benzinga
Topics Government
Exposures Political
Earnings Scheduled For May 7, 2025
Via Benzinga
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Via Benzinga
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Via Stocktwits
Topics Government
Exposures Political
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Via Benzinga
Topics Government
Exposures Political
Deal Dispatch: Nestlé, Coinbase, OpenAI Lead Diverse M&A Lineup As WeightWatchers Goes Bankrupt
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
Via Benzinga
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Via Benzinga
Topics ETFs Government
Exposures Political
Investors should take note of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.
Via Chartmill
Hims & Hers Has a Superpower in Healthcare
Via The Motley Fool
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
Topics Earnings Government World Trade
Exposures Financial Political Tariff
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Via Benzinga
Exposures Product Safety
Why Novo Nordisk Stock Popped After Earnings
Via The Motley Fool
Novo Nordisk Predicts Strong Second Half
Via The Motley Fool
Exposures Product Safety
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated
Via Stocktwits
Topics Earnings Law Enforcement
Exposures Financial Legal
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Via Benzinga
Topics Earnings
Exposures Financial
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump.
Via Investor's Business Daily
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth
Via The Motley Fool
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed
Via Benzinga
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Via The Motley Fool
Topics Earnings
Exposures Financial

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 67.74
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 05/12/25 06:30 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.